Psychiatry & Neurology Doctors in Omaha, TX Accepting Medicare
1 Psychiatry & Neurology doctors found. Showing 1 - 1
 Amelia L Stevens, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 101 Joyner St, Omaha, TX 75571 Phone: 903-884-2433 |
News Archive
Smartphone app can quickly screen for cognitive dysfunction in patients with cirrhosis
A smartphone app can quickly screen for cognitive dysfunction often found in patients with cirrhosis, according to a new Virginia Commonwealth University study. The cognitive dysfunction, known as minimal hepatic encephalopathy (MHE), has been difficult to diagnose.
Mylan receives final FDA approval for Pramipexole Dihydrochloride Tablets
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.
Study shows abused women suffering from PTSD do not receive adequate mental health services
Although many abused women suffer from Posttraumatic Stress Disorder (PTSD) and/or depression, they are not receiving needed mental health services, a University of Missouri researcher found.
The Blood Alliance signs agreement to implement Interactive Softworks' software
Interactive Softworks, a provider of customer engagement solutions, announced today that The Blood Alliance, a non-profit community blood bank, has signed an agreement to implement the company's software to recruit blood donors and schedule appointments. This implementation will enable The Blood Alliance to significantly improve its donor outreach program, increase operating efficiencies and drive more effective communications with donors.
Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
› Verified 2 days ago